Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Lipocine (LPCN) over the last 12 years, with Q3 2025 value amounting to 0.41%.

  • Lipocine's Return on Capital Employed fell 1500.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.05% for FY2024, which is 5900.0% up from last year.
  • According to the latest figures from Q3 2025, Lipocine's Return on Capital Employed is 0.41%, which was down 1500.0% from 0.31% recorded in Q2 2025.
  • Lipocine's 5-year Return on Capital Employed high stood at 0.08% for Q3 2022, and its period low was 0.84% during Q4 2023.
  • Over the past 5 years, Lipocine's median Return on Capital Employed value was 0.38% (recorded in 2021), while the average stood at 0.31%.
  • Per our database at Business Quant, Lipocine's Return on Capital Employed surged by 10500bps in 2021 and then crashed by -7900bps in 2023.
  • Quarter analysis of 5 years shows Lipocine's Return on Capital Employed stood at 0.08% in 2021, then crashed by -527bps to 0.33% in 2022, then crashed by -156bps to 0.84% in 2023, then surged by 93bps to 0.06% in 2024, then tumbled by -613bps to 0.41% in 2025.
  • Its Return on Capital Employed was 0.41% in Q3 2025, compared to 0.31% in Q2 2025 and 0.32% in Q1 2025.